Market Research Reports and Industry Reports

Neuropathic Pain - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Neuropathic Pain - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 114, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 7
Neuropathic Pain - Overview 8
Neuropathic Pain - Therapeutics Development 9
Neuropathic Pain - Therapeutics Assessment 36
Neuropathic Pain - Companies Involved in Therapeutics Development 53
Neuropathic Pain - Drug Profiles 102
Neuropathic Pain - Dormant Projects 429
Neuropathic Pain - Discontinued Products 447
Neuropathic Pain - Product Development Milestones 452
Appendix 463


List Of Tables


Number of Products under Development for Neuropathic Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2017
Neuropathic Pain - Pipeline by AbbVie Inc, H2 2017
Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2017
Neuropathic Pain - Pipeline by AnaBios Corp, H2 2017
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2 2017
Neuropathic Pain - Pipeline by AngioChem Inc, H2 2017
Neuropathic Pain - Pipeline by Aptinyx Inc, H2 2017
Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2 2017
Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2017
Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
Neuropathic Pain - Pipeline by BCI Pharma, H2 2017
Neuropathic Pain - Pipeline by BCN Peptides SA, H2 2017
Neuropathic Pain - Pipeline by Biogen Inc, H2 2017
Neuropathic Pain - Pipeline by Bionomics Ltd, H2 2017
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Co, H2 2017
Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Celgene Corp, H2 2017
Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2017
Neuropathic Pain - Pipeline by Cerecor Inc, H2 2017
Neuropathic Pain - Pipeline by Chromocell Corp, H2 2017
Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Colby Pharmaceutical Co, H2 2017
Neuropathic Pain - Pipeline by ConSynance Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2 2017
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Neuropathic Pain - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2017
Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2 2017
Neuropathic Pain - Pipeline by Eisai Co Ltd, H2 2017


List Of Figures


Number of Products under Development for Neuropathic Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017


Neuropathic Pain - Pipeline Review, H2 2017

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected and commonly accompanied by tissue injury.

USD 2000View Report

Peripheral Neuropathic Pain - Pipeline Insight, 2017

DelveInsights, Peripheral Neuropathic Pain-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Peripheral Neuropathic Pain. The report provides a complete understanding of the pipeline

USD 1250View Report

Dental Pain - Pipeline Review, H2 2017

Dental Pain - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2017, provides an overview of the Dental Pain

USD 2000View Report

Bulk/HOD Water (Soft drinks) Market in Spain - Outlook to 2021: Market Size, Growth and Forecast Analytics

Bulk/HOD Water (Soft drinks) Market in Spain - Outlook to 2021: Market Size, Growth and Forecast AnalyticsBulk/HOD Water (Soft drinks) Market in Spain - Outlook to 2021: Market Size, Growth

USD 500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :488
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube